Gilead dragged down by AbbVie's V-Pak miss

• Gilead Sciences (NASDAQ:GILD) is feeling some of AbbVie's (NYSE:ABBV) pain in premarket trading. Shares are down 4% on robust volume while AbbVie slumps 3% on average volume.
• AbbVie's Q4 U.S. sales of HCV med V-Pak were $197M, down almost 19% sequentially from Q3's $242M.